TIMP-1 Inhibitors
Common TIMP-1 Inhibitors include, but are not limited to Batimastat CAS 130370-60-4, Marimastat CAS 154039-60-8, TAPI-1 CAS 171235-71-5, Thalidomide CAS 50-35-1 and Veliparib CAS 912444-00-9.
TIMP-1 inhibitors form a distinct chemical class of compounds engineered to selectively target and modulate the activity of TIMP-1, a critical regulator of the extracellular matrix (ECM) remodeling process. The ECM provides structural support to tissues and plays a crucial role in cell adhesion, migration, and signaling. TIMP-1's primary function is to control the activity of matrix metalloproteinases (MMPs), a group of enzymes responsible for ECM degradation and tissue remodeling. By inhibiting TIMP-1, these compounds aim to disrupt its interactions with MMPs, leading to altered MMP activity and ECM remodeling. The delicate balance between MMP-mediated degradation and TIMP-1-mediated inhibition is vital for tissue homeostasis, wound healing, and maintaining tissue integrity. Modulating TIMP-1 activity through these inhibitors may have wide-ranging effects on various cellular processes beyond ECM remodeling. For example, changes in TIMP-1 levels could impact cell migration, immune responses, and the regulation of inflammatory pathways. By selectively inhibiting TIMP-1, researchers can gain insights into the multifaceted roles this protein plays in different physiological and pathological conditions.
The chemical structures and mechanisms of action of TIMP-1 inhibitors vary, and researchers continue to explore and optimize these compounds to enhance their selectivity and efficacy. Understanding the intricacies of TIMP-1 regulation and its interactions with MMPs through these inhibitors contribute to the development of strategies for managing conditions characterized by dysregulated ECM remodeling. Scientists are diligently working to unravel the complexities of TIMP-1's role in cellular functions, paving the way for future approaches targeting this critical component of ECM regulation. By studying TIMP-1 inhibition, researchers aim to advance our knowledge of cellular biology and its impact on tissue function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor. It inhibits multiple MMPs, including MMP-1, -2, -3, -7, -9, and -14. As TIMP-1 is a natural inhibitor of MMPs, Batimastat indirectly affects TIMP-1 by preventing the activity of MMPs that TIMP-1 would typically regulate. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat, like Batimastat, is a broad-spectrum matrix metalloproteinase (MMP) inhibitor. It inhibits multiple MMPs, including MMP-1, -2, -3, -7, -9, and -14. As TIMP-1 is a natural inhibitor of MMPs, Marimastat indirectly affects TIMP-1 by preventing the activity of MMPs that TIMP-1 would typically regulate. By inhibiting MMPs, Marimastat can modulate extracellular matrix remodeling. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
Prinomastat is another broad-spectrum matrix metalloproteinase (MMP) inhibitor. It inhibits multiple MMPs, including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, and MMP-14. As TIMP-1 is a natural inhibitor of MMPs, Prinomastat indirectly affects TIMP-1 by preventing the activity of MMPs that TIMP-1 would typically regulate. By inhibiting MMPs, Prinomastat can modulate extracellular matrix remodeling. | ||||||
TAPI-1 | 171235-71-5 | sc-222337 | 1 mg | $669.00 | 15 | |
TAPI-1 is a synthetic inhibitor that targets TNF-alpha converting enzyme (TACE), also known as ADAM17, an enzyme that plays a role in the shedding of cell surface proteins, including TIMP-1. By inhibiting TACE, TAPI-1 can decrease the release of TIMP-1 from the cell surface, potentially affecting TIMP-1-mediated processes. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide has a pleiotropic effects on the immune system and tumor microenvironment. It has been reported to downregulate TIMP-1 expression in certain cancer cells, leading to decreased extracellular matrix remodeling and tumor invasiveness. The exact mechanism by which Thalidomide affects TIMP-1 expression is not fully understood, but it may involve indirect modulation of transcription factors or signaling pathways that regulate TIMP-1 gene expression. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Cilengitide is an integrin antagonist that targets αvβ3 and αvβ5 integrins involved in cell adhesion, migration, and angiogenesis. Its direct effect on TIMP-1 is unclear, but by inhibiting integrin-mediated signaling, it may impact cellular processes regulated by TIMP-1 and MMPs. This disruption can affect extracellular matrix remodeling and potentially modulate TIMP-1's regulatory role. | ||||||
Doxycycline-d6 | 564-25-0 unlabeled | sc-218274 | 1 mg | $16500.00 | ||
Doxycycline is a tetracycline antibiotic that can decrease TIMP-1 expression in certain experimental models. May involve inhibiting pro-inflammatory signaling or transcription factors that regulate TIMP-1 gene expression. Lower TIMP-1 levels can affect the balance between matrix metalloproteinases (MMPs) and their inhibitors, potentially influencing tissue remodeling and inflammation. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib, a PARP inhibitor, shows anti-cancer properties, but its direct effect on TIMP-1 is unclear. By inhibiting PARP-mediated DNA repair pathways, Veliparib may influence gene expression related to extracellular matrix remodeling and tissue homeostasis. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin's impact on TIMP-1 expression is not well-established, but some studies suggest it may reduce TIMP-1 levels in certain cancer cells. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
Tanespimycin, also known as 17-AAG, is a HSP90 inhibitor. HSP90 stabilizes client proteins, including TIMP-1. By inhibiting HSP90, Tanespimycin can lead to TIMP-1 and other client proteins' degradation. This destabilization may impact extracellular matrix remodeling and the balance between MMPs and their inhibitors. | ||||||